InsiderTrades.com logo
Martin Edwards net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Martin Edwards Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share
Dr Edwards has significant experience in investing and contributing to the development of biotech companies in both Europe and the US. Dr Edwards currently serves on the boards of Inozyme Pharma, Morphic Therapeutic and Reata Pharmaceuticals. Previously, he was Senior Partner at Novo Ventures from 2003-2020, and Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development. Dr Edwards trained in physiology and medicine at the University of Manchester. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds a MBA from the University of Warwick.

What is Martin Edwards' net worth?

The estimated net worth of Martin Edwards is at least $16.89 million as of August 1st, 2025. Dr. Edwards owns 157,992 shares of Verona Pharma PLC American Depositary Share stock worth more than $16,890,925 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Edwards may own. Learn More about Martin Edwards' net worth.

How do I contact Martin Edwards?

The corporate mailing address for Dr. Edwards and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Martin Edwards' contact information.

Has Martin Edwards been buying or selling shares of Verona Pharma PLC American Depositary Share?

Martin Edwards has not been actively trading shares of Verona Pharma PLC American Depositary Share during the past quarter. Most recently, Martin Edwards sold 10,808 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $142,017.12. Following the completion of the sale, the director now directly owns 157,992 shares of the company's stock, valued at $2,076,014.88. Learn More on Martin Edwards' trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Martin Edwards Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell10,808$13.14$142,017.12157,992View SEC Filing Icon  
11/20/2023Buy33,736$1.84$62,074.24144,800View SEC Filing Icon  
See Full Table

Martin Edwards Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Martin Edwards's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05